How does Mazdutide peptide powder solve the double dilemma of obesity and diabetes?
1.Background: The 'dual challenge' of metabolic diseases
More than 650 million adults worldwide suffer from obesity, of which more than 40% are complicated with type 2 diabetes. Traditional weight loss drugs often have gastrointestinal side effects or rely on daily administration, leading to insufficient patient compliance. In June 2025, the China National Medical Products Administration approved Mazdutide peptide powder for chronic weight management, becoming the world's first GLP-1/GCGR dual agonist. Its unique mechanism can activate GLP-1 receptors to suppress appetite and increase energy expenditure through GCGR receptors, providing a new option for patients with metabolic diseases.
2.How effective is Mazdutide peptide powder in the field of weight loss?
2.1 Performance of different clinical trials
In some trials targeting overweight or obese individuals, it has demonstrated strong weight loss capabilities. For example, in a study conducted on overweight or obese subjects in China, after continuous administration for 24 weeks, there was a significant decrease in weight in different dose groups. The least squares mean of the percentage change in body weight relative to baseline in the 6.0mg group reached -11.57% (-9.85kg), while the placebo group only had 1.05% (1.08kg), indicating a significant comparison.
There is also a clinical trial in which subjects who received higher doses of the drug for 48 weeks lost nearly 15% weight, and liver fat decreased by 80% after receiving the higher dose of the drug. Bloomberg Intelligence analysts say that its weight loss effect is largely comparable to the weight loss achieved by the Eli Lilly Zepbound.
2.2 Advantages brought by unique mechanisms
Mazdutide peptide powder is a dual agonist of glucagon like peptide-1 receptor (GLP-1 R) and glucagon receptor (GCGR). It induces satiety inhibition through GLP-1R activation, thereby reducing dietary intake; Further stimulation through GCGR leads to an increase in energy consumption. This dual pronged approach, starting from reducing intake and increasing consumption, can more effectively achieve weight loss goals.
2.3 Comparison with other products
Compared with traditional weight loss products and single target GLP-1 drugs, Mazdutide's dual target mechanism has more advantages in weight loss, visceral fat reduction, and synchronous improvement of multiple metabolic indicators, especially suitable for obese patients with complex conditions such as fatty liver and hypertension.
If you have weight loss needs,Mazdutide peptide powder is a medication worth paying attention to, but specific use still needs to follow medical advice.
3.What is the weight loss principle of Mazdutide peptide powder?
3.1 Mazdutide achieves weight loss through dual target synergy
Mazdutide, also known as Masdutide, is a dual agonist of glucagon like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR). By simultaneously activating these two receptors, it precisely intervenes in energy balance, inhibits appetite, and accelerates metabolism.
3.2 Appetite suppression
After activation, GLP-1R can promote insulin release, increase pancreatic beta cell regeneration, inhibit beta cell apoptosis, and reduce glucagon release. In gastrointestinal tissues, it binds with agonists to inhibit gastrointestinal peristalsis and gastric juice secretion, delay gastric emptying, and make people more likely to feel full, thereby reducing calorie intake. For example, it's like adding a "speed bump" to the stomach to slow down food digestion, so we won't feel hungry quickly and naturally eat less.
3.3 Accelerated metabolism
Activating GCGR can promote liver fat oxidation, increase energy consumption, especially for visceral fat, which is very beneficial for health. For example, it can make the body function like an efficient "fat burner", converting excess fat into energy to help reduce weight.
4.What groups of people are suitable for using Mazdutide peptide powder?
4.1 Specific Applicable Population
Obese population: Adult obese patients with an initial body mass index (BMI) ≥ 28kg/m ² can benefit from Mazdutide's ability to suppress appetite and accelerate metabolism, helping them lose weight. For example, in some clinical trials, many obese patients have shown significant weight loss after use.
Overweight population with comorbidities: Overweight adult patients with BMI ≥ 24kg/m ² and at least one weight related complication, such as hyperglycemia, hypertension, dyslipidemia, etc., are also suitable for use. It can not only reduce weight, but also simultaneously improve key metabolic indicators such as blood sugar, blood lipids, and blood pressure.
Patients with type 2 diabetes: this drug can promote insulin secretion, reduce blood sugar, effectively reduce glycosylated hemoglobin (HbA1c), reduce blood sugar fluctuations, and help patients with type 2 diabetes control their condition.
4.2 Usage Suggestions
Although Mazdutide has therapeutic effects on these populations, it is necessary to strictly follow medical advice when using it, gradually increase the starting dose, and regularly evaluate tolerance and efficacy to ensure personalized treatment. At the same time, it is necessary to evaluate cardiac function before treatment, monitor heart rate changes during medication, and promptly address allergic reactions and discomfort at the injection site.
5.Conclusion: A 'new paradigm' for the treatment of metabolic diseases
Mazdutide peptide powder has initiated phase III clinical trials targeting non-alcoholic fatty liver disease (NASH). Its "once a week, multiple benefits" characteristic is expected to reshape the treatment pattern of metabolic diseases.It can be seen that Mazdutide has a broad development prospect in the pharmaceutical market and is expected to bring new treatment options for obese and diabetes patients.
Xi'an Faithful BioTech provide you with the highest quality Mazdutide peptide powder ，Purity>99%.Please contact me！E-mail ：sales10@faithfulbio.com .Our company will reply to you with detailed information as soon as possible.
Reference
1. Mazdutide,2259884-03-0[2025-06-05]
2. Mazdutide specification: g [2400-01-28]
3. Dimension of Furstenberg measures on $\mathbb{CP}^{1}$[2025-11-01]
4. A new weight loss therapy can reduce the weight of overweight/obese adults in China by 11.7%! [2022-10-19]
5.Weight loss medicine Mazdutide approved for commercialization in China[2025-07-02]
6.Improving time series estimation and prediction via transfer learning[2025-10-29]
7.Quantizer Design for Finite Model Approximations, Model Learning, and Quantized Q-Learning for MDPs with Unbounded Spaces[2025-10-05]
8. Mazdutide (IBI362) completed the first subject administration in the Phase III clinical study (DREAMS-1) of Chinese type 2 diabetes subjects [January 10, 2003]
9. Mazdutide (IBI362)'s Phase Ib clinical research results in Chinese subjects with type 2 diabetes were listed in NatureCommunications [202-06-29]
10. Front Endocrinol: The effectiveness and safety of Mazdutide in reducing weight in diabetes and non diabetes patients Metz Medicine [July 15, 2024]
11. The effect of the weight loss drug mazdutide is similar to that of the Eli Lilly Zeppound [June 26, 2024]
12. 'Three birds with one arrow'! New drugs not only reduce weight and eliminate fatty liver, but also improve cardiovascular metabolic risks | ADA 2024 Express [June 24, 2024]
13. Mazdutide demonstrates outstanding strength in the dual battlefield of weight loss and metabolic improvement. [2020-08-26]
14. Phase II clinical study and development of mazdutide treatment for overweight or obese patients to achieve the primary endpoint [June 8, 2022]
15. The efficacy of Mazdutide, a new drug for diabetes, in the treatment of diabetes [2023-02-20]
